{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:20:19Z","timestamp":1761895219426},"reference-count":53,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2010,12,4]]},"DOI":"10.1182\/asheducation-2010.1.310","type":"journal-article","created":{"date-parts":[[2011,1,16]],"date-time":"2011-01-16T19:08:48Z","timestamp":1295204928000},"page":"310-313","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":6,"title":["Evidence-Based Mini-Review: Treatment Options for Patients with Relapsed\/Refractory Myeloma Previously Treated with Novel Agents and High-Dose Chemotherapy and Autologous Stem-Cell Transplantation"],"prefix":"10.1182","volume":"2010","author":[{"given":"Nina","family":"Shah","sequence":"first","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sagar","family":"Lonial","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute, Emory University, Atlanta, GA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2019111523370333300_B1","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"2019111523370333300_B2","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1080\/10428190903085936","article-title":"Toxicity of a second autologous peripheral blood stem cell transplant in patients with relapsed or recurrent multiple myeloma","volume":"50","author":"Burzynski","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"2019111523370333300_B3","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/ajh.20641","article-title":"Prolonged overall survival with second on-demand autologous transplant in multiple myeloma","volume":"81","author":"Elice","year":"2006","journal-title":"Am J Hematol"},{"key":"2019111523370333300_B4","first-page":"275","article-title":"Second autologous transplantation for multiple myeloma patients relapsing after the first autograft \u2013 a pilot study for the evaluation of experimental maintenance therapies. Report of the prospective non-randomized pilot study of the Czech Myeloma Group","volume":"27","author":"Krivanova","year":"2004","journal-title":"Onkologie"},{"key":"2019111523370333300_B5","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/bmt.2008.334","article-title":"Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma","volume":"43","author":"Olin","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"2019111523370333300_B6","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1002\/cncr.21700","article-title":"Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma","volume":"106","author":"Qazilbash","year":"2006","journal-title":"Cancer"},{"key":"2019111523370333300_B7","first-page":"141","article-title":"The role of second autografts in the management of myeloma at first relapse","volume":"91","author":"Alvares","year":"2006","journal-title":"Haematologica"},{"key":"2019111523370333300_B8","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1200\/JCO.1995.13.6.1312","article-title":"Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma","volume":"13","author":"Gahrton","year":"1995","journal-title":"J Clin Oncol"},{"key":"2019111523370333300_B9","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.bbmt.2004.06.002","article-title":"Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan\/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma","volume":"10","author":"Kroger","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"key":"2019111523370333300_B10","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1182\/blood-2005-09-3869","article-title":"Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99\u201303 trial) with tandem autologous stem cell transplantation (IFM99\u201304 trial) in high-risk de novo multiple myeloma","volume":"107","author":"Garban","year":"2006","journal-title":"Blood"},{"key":"2019111523370333300_B11","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1182\/blood-2006-04-015909","article-title":"A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma","volume":"108","author":"Richardson","year":"2006","journal-title":"Blood"},{"key":"2019111523370333300_B12","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N Engl J Med"},{"key":"2019111523370333300_B13","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"key":"2019111523370333300_B14","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"key":"2019111523370333300_B15","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2141.2008.07409.x","article-title":"High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program","volume":"144","author":"Mikhael","year":"2009","journal-title":"Br J Haematol"},{"key":"2019111523370333300_B16","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2141.2004.05188.x","article-title":"A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma","volume":"127","author":"Jagannath","year":"2004","journal-title":"Br J Haematol"},{"key":"2019111523370333300_B17","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1182\/blood.V110.11.412.412","article-title":"Prolonged overall survival with lenalidomide plus dexamethasone compared with dexamethasone alone in patients with relapsed or refractory multiple myeloma [Abstract]","volume":"110","author":"Weber","year":"2007","journal-title":"Blood"},{"key":"2019111523370333300_B18","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1182\/blood-2008-02-141614","article-title":"Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure","volume":"112","author":"Wang","year":"2008","journal-title":"Blood"},{"issue":"4","key":"2019111523370333300_B19","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1365-2141.2009.07875.x","article-title":"Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed\/refractory multiple myeloma","volume":"147","author":"Vogl","year":"2009","journal-title":"Br J Haematol"},{"issue":"34","key":"2019111523370333300_B20","doi-asserted-by":"crossref","first-page":"5713","DOI":"10.1200\/JCO.2009.22.2679","article-title":"Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed\/refractory multiple myeloma","volume":"27","author":"Richardson","year":"2009","journal-title":"J Clin Oncol"},{"key":"2019111523370333300_B21","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/10428190500272721","article-title":"Low dose Velcade, thalidomide and dexamethasone (LD-VTD): an effective regimen for relapsed and refractory multiple myeloma patients","volume":"47","author":"Ciolli","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"2019111523370333300_B22","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1200\/JCO.2006.10.5460","article-title":"Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression","volume":"25","author":"Orlowski","year":"2007","journal-title":"J Clin Oncol"},{"key":"2019111523370333300_B23","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1002\/cncr.23326","article-title":"Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide\/lenalidomide therapy","volume":"112","author":"Sonneveld","year":"2008","journal-title":"Cancer"},{"key":"2019111523370333300_B24","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1093\/annonc\/mdl313","article-title":"Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy","volume":"17","author":"Baz","year":"2006","journal-title":"Ann Oncol"},{"issue":"5","key":"2019111523370333300_B25","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00277-009-0856-x","article-title":"Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study","volume":"89","author":"Kim","year":"2010","journal-title":"Ann Hematol"},{"issue":"3","key":"2019111523370333300_B26","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1365-2141.2010.08250.x","article-title":"The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed\/refractory myeloma patients; a phase I\/II study","volume":"150","author":"Schey","year":"2010","journal-title":"Br J Haematol"},{"key":"2019111523370333300_B27","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.1200\/JCO.2007.14.2372","article-title":"Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma","volume":"26","author":"Reece","year":"2008","journal-title":"J Clin Oncol"},{"key":"2019111523370333300_B28","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1365-2141.2007.06656.x","article-title":"Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma","volume":"138","author":"Kropff","year":"2007","journal-title":"Br J Haematol"},{"key":"2019111523370333300_B29","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/j.1365-2141.2008.07572.x","article-title":"Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma","volume":"144","author":"Popat","year":"2009","journal-title":"Br J Haematol"},{"issue":"5","key":"2019111523370333300_B30","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/leu.2010.58","article-title":"Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed\/refractory multiple myeloma","volume":"24","author":"Palumbo","year":"2010","journal-title":"Leukemia"},{"key":"2019111523370333300_B31","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1038\/leu.2008.235","article-title":"The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed\/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis","volume":"22","author":"Terpos","year":"2008","journal-title":"Leukemia"},{"key":"2019111523370333300_B32","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s00277-008-0501-0","article-title":"Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1\/2 study after longer follow-up","volume":"87","author":"Berenson","year":"2008","journal-title":"Ann Hematol"},{"key":"2019111523370333300_B33","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1182\/blood-2006-08-042275","article-title":"Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma","volume":"109","author":"Palumbo","year":"2007","journal-title":"Blood"},{"key":"2019111523370333300_B34","first-page":"PO-625","article-title":"Doxil + velcade in previously treated myeloma with prior SCT [Abstract]","volume":"92","author":"Nagler","year":"2007","journal-title":"Haematologica"},{"issue":"1","key":"2019111523370333300_B35","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3816\/CLML.2010.n.008","article-title":"Weekly bortezomib, pegylated liposomal doxorubicin, and dexamethasone is a safe and effective therapy for elderly patients with relapsed\/refractory multiple myeloma","volume":"10","author":"Gozzetti","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2019111523370333300_B36","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1080\/10428190902912460","article-title":"Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial","volume":"50","author":"Chanan-Khan","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"2019111523370333300_B37","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/j.1365-2141.2008.07147.x","article-title":"The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma","volume":"141","author":"Ciolli","year":"2008","journal-title":"Br J Haematol"},{"issue":"5","key":"2019111523370333300_B38","doi-asserted-by":"crossref","first-page":"937","DOI":"10.3109\/10428191003695660","article-title":"Frail elderly patients with relapsed-refractory multiple myeloma: efficacy and toxicity profile of the combination of bortezomib, high-dose dexamethasone, and low-dose oral cyclophosphamide","volume":"51","author":"Mele","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"2019111523370333300_B39","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1182\/blood-2008-10-184135","article-title":"Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom)","volume":"113","author":"Knop","year":"2009","journal-title":"Blood"},{"key":"2019111523370333300_B40","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1093\/annonc\/mdn018","article-title":"Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma","volume":"19","author":"Palumbo","year":"2008","journal-title":"Ann Oncol"},{"issue":"9","key":"2019111523370333300_B41","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s00277-010-0943-z","article-title":"Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety","volume":"89","author":"Lee","year":"2010","journal-title":"Ann Hematol"},{"key":"2019111523370333300_B42","doi-asserted-by":"crossref","first-page":"5250","DOI":"10.1158\/1078-0432.CCR-08-2850","article-title":"Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma","volume":"15","author":"Badros","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2019111523370333300_B43","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3816\/CLML.2010.n.022","article-title":"Vorinostat plus bortezomib for the treatment of relapsed\/refractory multiple myeloma: a case series illustrating utility in clinical practice","volume":"10","author":"Mazumder","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2019111523370333300_B44","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1080\/10428190701817258","article-title":"Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma","volume":"49","author":"Richardson","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"2019111523370333300_B45","doi-asserted-by":"crossref","article-title":"Phase I study of combined vorinostat (V), lenalidomide (L), and dexamethasone (D) in patients (pts) with relapsed or refractory multiple myeloma (MM) [Abstract]","author":"Richardson","DOI":"10.1200\/jco.2010.28.15_suppl.8031"},{"key":"2019111523370333300_B46","doi-asserted-by":"crossref","article-title":"Phase Ib study of oral panobinostat (LBH589) plus intravenous bortezomib in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM) [Abstract]","author":"San-Miguel","DOI":"10.1200\/jco.2010.28.15_suppl.8001"},{"key":"2019111523370333300_B47","doi-asserted-by":"crossref","article-title":"Phase Ib study of oral panobinostat (LBH589) plus lenalidomide (LEN) plus dexamethasone (DEX) in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM) [Abstract]","author":"Mateos","DOI":"10.1200\/jco.2010.28.15_suppl.8030"},{"key":"2019111523370333300_B48","doi-asserted-by":"crossref","article-title":"Results of an ongoing open-label, phase II study of carfilzomib in patients with relapsed and\/or refractory multiple myeloma (R\/R MM) [Abstract]","author":"Vij","DOI":"10.1200\/jco.2010.28.15_suppl.8000"},{"key":"2019111523370333300_B49","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.1200\/JCO.2009.23.6802","article-title":"Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma","volume":"27","author":"Lacy","year":"2009","journal-title":"J Clin Oncol"},{"key":"2019111523370333300_B50","article-title":"Activity of pomalidomide plus dexamethasone (Pom\/dex) in dual lenalidomide\/bortezomib refractory multiple myeloma (MM) [Abstract]","author":"Lacy"},{"key":"2019111523370333300_B51","doi-asserted-by":"crossref","article-title":"Elotuzumab in combination with bortezomib in patients with relapsed\/refractory multiple myeloma: A phase I study [Abstract]","author":"Jakubowiak","DOI":"10.1200\/jco.2010.28.15_suppl.8003"},{"key":"2019111523370333300_B52","doi-asserted-by":"crossref","article-title":"Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma: A phase I\/II study [Abstract]","author":"Lonial","DOI":"10.1200\/jco.2010.28.15_suppl.8020"},{"key":"2019111523370333300_B53","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/ajh.21517","article-title":"Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib","volume":"84","author":"Sood","year":"2009","journal-title":"Am J Hematol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2010\/1\/310\/1493670\/bep00110000310.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2010\/1\/310\/1493670\/bep00110000310.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T05:27:09Z","timestamp":1573882029000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2010\/1\/310\/278353\/EvidenceBased-MiniReview-Treatment-Options-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,4]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12,4]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2010.1.310","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,4]]}}}